Sleep medicine pharmacotherapeutics overview: Today, tomorrow, and the future (Part 1: Insomnia and circadian rhythm disorders)

Chest

Volumn 142, Issue 6, 2012, Pages 1659-1668

  Gulyani, Seema ^a   Salas, Rachel E ^a   Gamaldo, Charlene E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANACIN; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHAMOMILE; DIPHENHYDRAMINE; DOXEPIN; DOXYLAMINE; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; KAVA; MELATONIN; MIRTAZAPINE; NEFAZODONE; NITRAZEPAM; NORTRIPTYLINE; NYQUIL; PARACETAMOL; QUAZEPAM; RAMELTEON; SLEEPINAL; TEMAZEPAM; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN; ZALEPLON; ZOLPIDEM TARTRATE;

ADVANCED SLEEP PHASE DISORDER; AMNESIA; ANOREXIA; ATAXIA; BEDTIME DOSAGE; BLURRED VISION; CARDIOTOXICITY; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); DELAYED SLEEP PHASE DISORDER; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BINDING; DRUG DEPENDENCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DYSKINESIA; EUPHORIA; EYE PAIN; FALLING; FATIGUE; FOOD AND DRUG ADMINISTRATION; FREE RUNNING DISORDER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRREGULAR SLEEP WAKE RHYTHM; IRRITABILITY; JET LAG; LIVER TOXICITY; MEMORY DISORDER; NAUSEA; NERVOUSNESS; NEUROBIOLOGY; NONHUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEDATION; SHIFT WORK DISORDER; SIDE EFFECT; SKIN TINGLING; SLEEP DISORDERED BREATHING; SLURRED SPEECH; TASTE DISORDER; UNSTEADINESS; URINE RETENTION; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 84870602082     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0465     Document Type: Article

References (59)

1. International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
2. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey. Biol Psychiatry. 2011;69(6):592-600.
3. Mai E, Buysse DJ. Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Sleep Med Clin. 2008;3(2):167-174.
4. Morin CM, Bélanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med. 2009;169(5):447-453.
5. Ohayon MM, Guilleminault C, Chokroverty S. Sleep epidemiology 30 years later: where are we? Sleep Med. 2010;11(10):961-962.
6. Lu BS, Zee PC. Neurobiology of sleep. Clin Chest Med. 2010;31(2):309-318.
7. España RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep. 2011;34(7):845-858.
8. Zee PC. Shedding light on the effectiveness of melatonin for circadian rhythm sleep disorders. Sleep. 2010;33(12):1581-1582.
9. Dodson ER, Zee PC. Therapeutics for circadian rhythm sleep disorders. Sleep Med Clin. 2010;5(4):701-715.
10. Guardiola-Lemaître B. Toxicology of melatonin. J Biol Rhythms. 1997;12(6):697-706.
11. Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33(2):225-234.
12. Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther. 2006;112(3):612-629. (Pubitemid 44573490)
13. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol. 2007;3(4):221-228. (Pubitemid 46605272)
14. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev. 2009;13(4):265-274.
15. Ancoli-Israel S, Richardson GS, Mangano RM, Jenkins L, Hall P, Jones WS. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005;6(2):107-113. (Pubitemid 40247172)
16. Stone KL, Ensrud KE, Ancoli-Israel S. Sleep, insomnia and falls in elderly patients. Sleep Med. 2008;9(suppl 1):S18-S22.
17. Trewin VF, Lawrence CJ, Veitch GB. An investigation of the association of benzodiazepines and other hypnotics with the incidence of falls in the elderly. J Clin Pharm Ther. 1992;17(2):129-133.
18. Sullivan SS, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs. 2009;14(3):411-422.
19. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577-1601.
20. Eckert DJ, Owens RL, Kehlmann GB, et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci (Lond). 2011;120(12):505-514.
21. Heinzer RC, White DP, Jordan AS, et al. Trazodone increases arousal threshold in obstructive sleep apnoea. Eur Respir J. 2008;31(6):1308-1312.
22. Gooneratne NS, Gehrman P, Gurubhagavatula I, Al-Shehabi E, Marie E, Schwab R. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. J Clin Sleep Med. 2010;6(6):572-580.
23. Lettieri CJ, Shah AA, Holley AB, Kelly WF, Chang AS, Roop SA; CPAP Promotion and Prognosis-The Army Sleep Apnea Program Trial. Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med. 2009;151(10):696-702.
24. Bradshaw DA, Ruff GA, Murphy DP. An oral hypnotic medication does not improve continuous positive airway pressure compliance in men with obstructive sleep apnea. Chest. 2006;130(5):1369-1376. (Pubitemid 44786728)
25. Lettieri CJ, Collen JF, Eliasson AH, Quast TM. Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, double-blind, placebocontrolled trial. Chest. 2009;136(5):1263-1268.
26. Taylor DJ, Lichstein KL, Durrence HH. Insomnia as a health risk factor. Behav Sleep Med. 2003;1(4):227-247.
27. Mindell JA, Emslie G, Blumer J, et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006;117(6):e1223-e1232. (Pubitemid 46071221)
28. Johnson EO, Roth T, Schultz L, Breslau N. Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics. 2006;117(2):e247-e256. (Pubitemid 46071577)
29. Riemann D; Workshop Participants. Does effective management of sleep disorders reduce depressive symptoms and the risk of depression? Drugs. 2009;69(suppl 2):43-64.
30. Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry. 1998;44(1):3-14. (Pubitemid 28305536)
31. Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473-481.
32. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060. (Pubitemid 43849658)
33. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151(7):1069-1072. (Pubitemid 24208646)
34. Sack RL, Auckley D, Auger RR, et al American Academy of Sleep Medicine. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep. 2007;30(11):1484-1501. (Pubitemid 350036974)
35. Sack RL, Auckley D, Auger RR, et al American Academy of Sleep Medicine. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. Sleep. 2007;30(11):1460-1483. (Pubitemid 350036973)
36. Morgenthaler TI, Lee-Chiong T, Alessi C, et al Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep. 2007;30(11):1445-1459. (Pubitemid 350036972)
37. Ebisawa T. Circadian rhythms in the CNS and peripheral clock disorders: human sleep disorders and clock genes. J Pharmacol Sci. 2007;103(2):150-154. (Pubitemid 46294645)
38. Schrader H, Bovim G, Sand T. The prevalence of delayed and advanced sleep phase syndromes. J Sleep Res. 1993;2(1):51-55. (Pubitemid 23137511)
39. Dagan Y, Eisenstein M. Circadian rhythm sleep disorders: toward a more precise definition and diagnosis. Chronobiol Int. 1999;16(2):213-222. (Pubitemid 29186439)
40. Sharkey KM, Carskadon MA, Figueiro MG, Zhu Y, Rea MS. Effects of an advanced sleep schedule and morning short wavelength light exposure on circadian phase in young adults with late sleep schedules. Sleep Med. 2011;12(7):685-692.
41. Schwartz JR, Roth T. Shift work sleep disorder: burden of illness and approaches to management. Drugs. 2006;66(18):2357-2370. (Pubitemid 46072447)
42. Zee PC, Goldstein CA. Treatment of shift work disorder and jet lag. Curr Treat Options Neurol. 2010;12(5):396-411.
43. Ker K, Edwards PJ, Felix LM, Blackhall K, Roberts I. Caffeine for the prevention of injuries and errors in shift workers. Cochrane Database Syst Rev. 2010;(5):CD008508.
44. Sharkey KM, Eastman CI. Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study. Am J Physiol Regul Integr Comp Physiol. 2002;282(2):R454-R463. (Pubitemid 34664596)
45. Monchesky TC, Billings BJ, Phillips R, Bourgouin J. Zopiclone in insomniac shiftworkers. Evaluation of its hypnotic properties and its effects on mood and work performance. Int Arch Occup Environ Health. 1989;61(4):255-259. (Pubitemid 19071554)
46. Walsh JK, Schweitzer PK, Anch AM, Muehlbach MJ, Jenkins NA, Dickins QS. Sleepiness/alertness on a simulated night shift following sleep at home with triazolam. Sleep. 1991;14(2):140-146.
47. Porcù S, Bellatreccia A, Ferrara M, Casagrande M. Performance, ability to stay awake, and tendency to fall asleep during the night after a diurnal sleep with temazepam or placebo. Sleep. 1997;20(7):535-541. (Pubitemid 27415476)
48. Hart CL, Ward AS, Haney M, Foltin RW. Zolpidem-related effects on performance and mood during simulated night-shift work. Exp Clin Psychopharmacol. 2003;11(4):259-268. (Pubitemid 37433438)
49. Czeisler CA, Walsh JK, Roth T, et al U.S. Modafinil in Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med. 2005;353(5):476-486. (Pubitemid 41127292)
50. Czeisler CA, Walsh JK, Wesnes KA, Arora S, Roth T. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc. 2009;84(11):958-972.
51. Drake CL, Roehrs T, Richardson G, Walsh JK, Roth T. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep. 2004;27(8):1453-1462. (Pubitemid 40041612)
52. Sack RL. Clinical practice. Jet lag. N Engl J Med. 2010;362(5):440-447.
53. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;(2):CD001520.
54. Takahashi T, Sasaki M, Itoh H, et al. Melatonin alleviates jet lag symptoms caused by an 11-hour eastward flight. Psychiatry Clin Neurosci. 2002;56(3):301-302. (Pubitemid 34754890)
55. Zee PC, Wang-Weigand S, Wright KP Jr, Peng X, Roth T. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med. 2010;11(6):525-533.
56. Suhner A, Schlagenhauf P, Höfer I, Johnson R, Tschopp A, Steffen R. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviat Space Environ Med. 2001;72(7):638-646. (Pubitemid 32623095)
57. Paul MA, Miller JC, Gray GW, Love RJ, Lieberman HR, Arendt J. Melatonin treatment for eastward and westward travel preparation. Psychopharmacology (Berl). 2010;208(3):377-386.
58. Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. J Clin Endocrinol Metab. 1992;75(1):127-134.
59. Arendt J, Aldhous M, Wright J. Synchronisation of a disturbed sleep-wake cycle in a blind man by melatonin treatment. Lancet. 1988;331(8588):772-773. (Pubitemid 18075736)